dishman pharma (Emkay) Subdued performance to continue

Q4FY11 was above our expectations with a) Revenues at Rs3.44 bn (up 39% YoY), EBIDTA at Rs555 mn (up 12% YoY) and APAT at Rs214 mn (up 18% YoY)
Date Rating Target Price Recommendation Price Broker house
26 May 2011 accumulate 125 96 Emkay Report

No comments:

Post a Comment